RhumbLine Advisers
LENZ

RhumbLine Advisers’s LENZ Therapeutics LENZ Stock Holding History

RhumbLine Advisers’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$137K Buy
24,144
+1,668
+7% +$13.4K ﹤0.01% 3420
2026
Q1 		$206K Buy
22,476
+2,226
+11% +$31.3K ﹤0.01% 3104
2025
Q4 		$324K Sell
20,250
-4,769
-19% -$139K ﹤0.01% 2927
2025
Q3 		$1.17M Buy
25,019
+656
+3% +$24.1K ﹤0.01% 2163
2025
Q2 		$714K Buy
24,363
+6,396
+36% +$174K ﹤0.01% 2432
2025
Q1 		$462K Sell
17,967
-787
-4% -$19.4K ﹤0.01% 2629
2024
Q4 		$541K Buy
18,754
+1,100
+6% +$33.5K ﹤0.01% 2637
2024
Q3 		$419K Buy
17,654
+842
+5% +$18.7K ﹤0.01% 2821
2024
Q2 		$291K Buy
16,812
+12,214
+266% +$213K ﹤0.01% 3022
2024
Q1 		$103K Buy
4,598
+141
+3% +$2.93K ﹤0.01% 3439
2023
Q4 		$81.7K Sell
4,457
-359
-7% -$5.93K ﹤0.01% 3512
2023
Q3 		$83.6K Buy
4,816
+660
+16% +$11.5K ﹤0.01% 3517
2023
Q2 		$75.6K Buy
+4,156
New +$83K ﹤0.01% 3590
2022
Q2 		– Sell
-3,523
Closed -$126K – 3253
2022
Q1 		$126K Buy
3,523
+1,854
+111% +$116K ﹤0.01% 2847
2021
Q4 		$145K Sell
1,669
-9
-0.5% -$746 ﹤0.01% 2891
2021
Q3 		$193K Buy
+1,678
New +$248K ﹤0.01% 2921

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

RhumbLine Advisers's LENZ Position: Q2 2026 in Review

RhumbLine Advisers increased its LENZ Therapeutics (LENZ) stake by 7.4% in Q2 2026, buying an estimated $13.4K and bringing the position to 24,144 shares worth $137K. The position accounts for ﹤0.01% of the portfolio, ranked #3420.

RhumbLine Advisers first reported a position in LENZ in Q3 2021 and has held it in 16 quarters since. The position peaked at $1.17M in Q3 2025. 144 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • RhumbLine Advisers held 24,144 shares of LENZ Therapeutics worth $137K as of Q2 2026.
  • RhumbLine Advisers bought 1,668 LENZ Therapeutics shares in Q2 2026, an estimated $13.4K.
  • LENZ Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3420 holding.
  • RhumbLine Advisers first reported a position in LENZ Therapeutics in Q3 2021 and has held it in 16 quarters since.
  • RhumbLine Advisers's LENZ Therapeutics position peaked at $1.17M in Q3 2025.
  • 144 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.